MX366829B - Composiciones y formas de dosificacion de itraconazol y metodos de uso de las mismas. - Google Patents

Composiciones y formas de dosificacion de itraconazol y metodos de uso de las mismas.

Info

Publication number
MX366829B
MX366829B MX2015000179A MX2015000179A MX366829B MX 366829 B MX366829 B MX 366829B MX 2015000179 A MX2015000179 A MX 2015000179A MX 2015000179 A MX2015000179 A MX 2015000179A MX 366829 B MX366829 B MX 366829B
Authority
MX
Mexico
Prior art keywords
methods
same
dosage forms
compositions
itraconazole
Prior art date
Application number
MX2015000179A
Other languages
English (en)
Other versions
MX2015000179A (es
Inventor
James Mudge Stuart
Hayes David
Lukas Stefan
Original Assignee
Mayne Pharma Int Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2012902624A external-priority patent/AU2012902624A0/en
Application filed by Mayne Pharma Int Pty Ltd filed Critical Mayne Pharma Int Pty Ltd
Publication of MX2015000179A publication Critical patent/MX2015000179A/es
Publication of MX366829B publication Critical patent/MX366829B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

La presente invención está relacionada con composiciones y formas de dosificación de itraconazol, y métodos de uso de las mismas. La composición farmacéutica de la presente invención comprende aproximadamente 50 mg de itraconazol, en la que la composición presenta un AUC0-t que es del 80% al 125% de aproximadamente 440 h*ng/ml hasta aproximadamente 740 h*ng/ml después de la administración de la composición a un sujeto en condiciones de nutrición. La invención también proporciona un método de reducción del efecto de los alimentos del itraconazol en un sujeto.
MX2015000179A 2012-06-21 2013-06-21 Composiciones y formas de dosificacion de itraconazol y metodos de uso de las mismas. MX366829B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2012902624A AU2012902624A0 (en) 2012-06-21 Itraconazole formulations and uses
PCT/US2013/047135 WO2013192566A1 (en) 2012-06-21 2013-06-21 Itraconazole compositions and dosage forms, and methods of using the same

Publications (2)

Publication Number Publication Date
MX2015000179A MX2015000179A (es) 2016-02-16
MX366829B true MX366829B (es) 2019-07-25

Family

ID=49769445

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015000179A MX366829B (es) 2012-06-21 2013-06-21 Composiciones y formas de dosificacion de itraconazol y metodos de uso de las mismas.

Country Status (11)

Country Link
US (7) US8921374B2 (es)
EP (1) EP2863911A4 (es)
JP (2) JP2015531749A (es)
KR (3) KR20200065093A (es)
CN (2) CN109674795A (es)
AU (3) AU2013278001A1 (es)
BR (1) BR112014031706A2 (es)
CA (1) CA2876909C (es)
HK (1) HK1207288A1 (es)
MX (1) MX366829B (es)
WO (1) WO2013192566A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200065093A (ko) 2012-06-21 2020-06-08 메인 파마 인터내셔널 프로프라이어터리 리미티드 이트라코나졸 조성물 및 투여형, 그리고 이것들의 사용 방법
US9192609B2 (en) 2013-04-17 2015-11-24 Hedgepath Pharmaceuticals, Inc. Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors
WO2019040363A1 (en) 2017-08-20 2019-02-28 University Of Connecticut AZOLE-TYPE COMPOUND ANALOGUES AND METHODS OF USE
WO2019232110A1 (en) * 2018-05-30 2019-12-05 Mayne Pharma International Pty Ltd Hedgehog pathway inhibition for treatment of high-risk basal cell carcinoma or high-risk basal cell carcinoma nevus syndrome
WO2021226166A1 (en) 2020-05-07 2021-11-11 Liang Guibai Prodrug of itraconazole and use thereof
WO2023007514A1 (en) * 2021-07-29 2023-02-02 Dr. Reddy's Laboratories Limited Improved oral bioavailable pharmaceutical compositions

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3110794B2 (ja) 1991-06-05 2000-11-20 ユーシービージャパン株式会社 １，４−ジヒドロピリジン誘導体を含有する製剤
US5340591A (en) 1992-01-24 1994-08-23 Fujisawa Pharmaceutical Co., Ltd. Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine
PH30929A (en) 1992-09-03 1997-12-23 Janssen Pharmaceutica Nv Beads having a core coated with an antifungal and a polymer.
EP0784974B1 (en) 1995-07-26 2003-05-21 Kyowa Hakko Kogyo Co., Ltd. preparation of xanthine derivatives in a solid dispersion
IL124935A (en) 1996-05-20 2001-06-14 Janssen Pharmaceutica Nv Dissolvable fungicidal preparations contain itraconazole with improved bioavailability
DE69730241T2 (de) 1996-06-28 2005-08-11 Schering Corp. Feste lösung eines fungizids mit erhöhter bioverfügbarkeit
ES2185238T3 (es) 1997-12-31 2003-04-16 Choongwae Pharma Corp Preparado oral de itraconazol y su procedimiento de preparacion.
KR100336090B1 (ko) 1998-06-27 2002-05-27 윤승원 오일, 지방산 또는 이들의 혼합물을 함유한 난용성 약물의 고형분산제제
JP2002534371A (ja) 1999-01-06 2002-10-15 コリア リサーチ インスティテュート オブ ケミカル テクノロジー 水不溶性薬物を含む医薬的活性成分の製造方法及びそれを含む経口投与用医薬組成物
EP1027886B1 (en) 1999-02-10 2008-07-09 Pfizer Products Inc. Pharmaceutical solid dispersions
EP2415462A1 (en) * 1999-12-23 2012-02-08 Mayne Pharma International Pty Ltd. Improved pharmaceutical compositions for poorly soluble drugs
KR100425755B1 (ko) * 2001-08-27 2004-04-03 주식회사 원진신약 이트라코나졸을 함유하는 조성물 및 그 제조방법
US20050058670A1 (en) 2003-09-09 2005-03-17 Jong-Soo Woo Oral itraconazole composition which is not affected by ingested food and process for preparing same
KR100529766B1 (ko) 2003-09-09 2005-11-17 한미약품 주식회사 음식물 섭취에 따른 영향이 적은, 이트라코나졸경구투여용 조성물 및 이의 제조 방법
JP4342426B2 (ja) * 2004-11-24 2009-10-14 科研製薬株式会社 イトラコナゾール経口投与用製剤
WO2007017248A2 (en) * 2005-08-08 2007-02-15 Abbott Gmbh & Co. Kg Itraconazole compositions with improved bioavailability
AU2007265452A1 (en) * 2006-06-26 2008-01-03 Mutual Pharmaceutical Company, Inc. Active agent formulations, methods of making, and methods of use
WO2008124132A1 (en) * 2007-04-05 2008-10-16 The Johns Hopkins University Chirally pure isomers of itraconazole and inhibitors of lanosterol 14a- demethylase for use as angiogenesis inhibitors
KR20200065093A (ko) 2012-06-21 2020-06-08 메인 파마 인터내셔널 프로프라이어터리 리미티드 이트라코나졸 조성물 및 투여형, 그리고 이것들의 사용 방법

Also Published As

Publication number Publication date
AU2013278001A1 (en) 2015-01-22
US20210038728A1 (en) 2021-02-11
AU2018201298A1 (en) 2018-03-15
JP2015531749A (ja) 2015-11-05
MX2015000179A (es) 2016-02-16
EP2863911A1 (en) 2015-04-29
US10806792B2 (en) 2020-10-20
CA2876909C (en) 2022-08-16
KR20200065093A (ko) 2020-06-08
HK1207288A1 (en) 2016-01-29
CN104507480A (zh) 2015-04-08
KR20210043721A (ko) 2021-04-21
AU2018201298B2 (en) 2020-05-14
JP6757367B2 (ja) 2020-09-16
US9272046B2 (en) 2016-03-01
US10463740B2 (en) 2019-11-05
US9713642B2 (en) 2017-07-25
WO2013192566A1 (en) 2013-12-27
CA2876909A1 (en) 2013-12-27
US8921374B2 (en) 2014-12-30
US20190125879A1 (en) 2019-05-02
EP2863911A4 (en) 2016-07-13
US20160030582A1 (en) 2016-02-04
KR20150043296A (ko) 2015-04-22
US20170348421A1 (en) 2017-12-07
CN109674795A (zh) 2019-04-26
US20200138959A1 (en) 2020-05-07
BR112014031706A2 (pt) 2017-06-27
US20140005205A1 (en) 2014-01-02
AU2020217438A1 (en) 2020-09-03
US11638758B2 (en) 2023-05-02
JP2018162304A (ja) 2018-10-18
US20150099763A1 (en) 2015-04-09

Similar Documents

Publication Publication Date Title
AU2018236800B2 (en) DNA-PK inhibitors
MX2015010921A (es) Compuestos de carbazol utiles como inhibidores de bromodominio.
PH12015501648B1 (en) 2-aminopyrimidine derivatives for the treatment of viral infections
IN2014DN10386A (es)
PH12016500094A1 (en) Autotaxin inhibitors
PH12016501122A1 (en) Delayed release compositions of linaclotide
PH12015500724B1 (en) 1, 2, 4-triazine derivatives for the treatment of viral infections
MY193728A (en) Muscarinic receptor agonists
PH12014501991B1 (en) Phenicol antibacterials
PH12014501967A1 (en) Benzodioxanes in combination with other actives for inhibiting leukotriene production
UA117032C2 (uk) Селективний інгібітор фосфатидилінозитол-3-кінази-гамма
IN2013MU03583A (es)
IN2015DN02912A (es)
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
MX2014010433A (es) Nueva forma cristalina de sulfato de sitagliptina.
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
MX2015000179A (es) Composiciones y formas de dosificacion de itraconazol y metodos de uso de las mismas.
PH12016500495A1 (en) Compositions for the treatment of hypertension and/or fibrosis
MX2015016603A (es) Composiciones de corticosteroides.
MX2016004094A (es) Composicion farmaceutica que comprende capecitabina y ciclofosfamida.
WO2014122671A3 (en) Solid oral compositions of saxagliptin
IN2013MU03428A (es)
MX2014004742A (es) Nuevos agentes antibacterianos de fenicol.
IN2013MU03429A (es)
IN2013MU01927A (es)

Legal Events

Date Code Title Description
FG Grant or registration